PharmaSurgics develops novel treatments for the prevention of internal post-surgical scar formation, adhesions, which represent a problem of high unmet medical need.
The extensive problems associated with adhesions cause severe pain to millions of patients. It is also a world-wide dilemma for surgeons, and a major burden on health care systems.
Existing therapies have failed to show efficacy and have been associated with severe adverse effects or complicated handling.
PharmaSurgics’ peptides integrated into a lubricating vehicle covering all surfaces that are at risk of developing post surgical adhesions creates a state-of-the-art product for preventing adhesion formation. The combined effect of a physical barrier and a novel compound directly affecting the mechanism behind adhesion formation is unique. The product is designed to be easily applied before closure of a surgical incision and the concept is developed to be adaptable for several surgical procedures. The application of PharmaSurgics’ product in the flexor tendon indication is visualized to the left.
